374
Fogli S, Caraglia M. Genotype-based therapeutic approach for colorectal cancer: state of the art
and future perspectives. Expert Opin Pharmacother. 2009;10:1095–108.
Freedman AN, Slattery ML, Ballard-Barbash R, et al. A colorectal cancer risk prediction tool for
white men and women without known susceptibility. J Clin Oncol. 2009;27:686–93.
Fry RJ, Svensson JP, Valiathan C, et al. Genomic predictors of interindividual differences in
response to DNA damaging agents. Genes Dev. 2008;22:2621–6.
Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activ-
ity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010;16:399–403.
Garman KS, Acharya CR, Edelman E, et al. A genomic approach to colon cancer risk stratifi cation
yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A.
2008;105:19431–6.
Gates JD, Carmichael MG, Benavides LC, et al. Longterm followup assessment of a HER2/neu
peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am
Coll Surg. 2009;208:193–201.
Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred
from blood DNA sequence. N Engl J Med. 2014;371:2477–87.
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.
Giotopoulos G, Symonds RP, Foweraker K, et al. The late radiotherapy normal tissue injury phe-
notypes of telangiectasia, fi brosis and atrophy in breast cancer patients have distinct genotype-
dependent causes. Br J Cancer. 2007;96:1001–7.
Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associ-
ated with clinical outcomes of effi cacy and hot fl ashes. J Clin Oncol. 2005;23:9312–8.
Gómez-Raposo C, Mendiola M, Hardisson H, Redondo A. From targeted therapy in ovarian can-
cer to personalizing therapy for ovarian cancer. Expert Opin Invest Drugs. 2011;20:591–4.
Gong Y, Yan K, Lin F, et al. Determination of oestrogen-receptor status and ERBB2 status of
breast carcinoma: a gene-expression profi ling study. Lancet Oncol. 2007;8:203–11.
Grauden E, Boulanger V, Mollard C, et al. Deciphering cellular states of innate tumor drug
responses. Genome Biol. 2006;7:R19.
Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state
to promote cancer metastasis. Nature. 2010;464:1071–6.
Halo TL, McMahon KM, Angeloni NL, et al. NanoFlares for the detection, isolation, and culture
of live tumor cells from human blood. Proc Natl Acad Sci U S A. 2014;111:17104–9.
Hanna E, Shrieve DC, Ratanatharathorn V, et al. A novel alternative approach for prediction of
radiation response of squamous cell carcinoma of head and neck. Cancer Res.
2001;61:2376–80.
Hanna MG, Hoover HC, Pinedo HM, Finer M. Active specifi c immunotherapy with autologous
tumor cell vaccines for stage II colon cancer. Hum Vaccin. 2006;2:185–91.
Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following
taxane- anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305:1873–81.
Hawkins RE, Gilham DE, Debets R, et al. Development of adoptive cell therapy for cancer: a clini-
cal perspective. Hum Gene Ther. 2010;21:665–72.
Haynes HR, Camelo-Piragua S, Kuria KM. Prognostic and predictive biomarkers in adult and
pediatric gliomas: toward personalized treatment. Front Oncol. 2014;4:47.
Heiser LM, Sadanandam A, Kuo WL, et al. Subtype and pathway specifi c responses to anticancer
compounds in breast cancer. Proc Natl Acad Sci U S A. 2012;109:2724–9.
Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat
Rev Cancer. 2008;8:193–204.
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind,
placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in
advanced prostate cancer. Cancer. 2009;115:3670–9.
Holzinger D, Schmitt M, Dyckhoff G, et al. Viral RNA patterns and high viral load reliably defi ne
oropharynx carcinomas with active HPV16 involvement. Cancer Res. 2012;72:4993–5003.
10 Personalized Therapy of Cancer